Fractyl Completes Randomization in REMAIN-1 Revita Trial

Fractyl Health, Inc. ( (GUTS) ) has issued an announcement.

Fractyl Health, Inc. announced on Feb. 26, 2026, that it has completed participant randomization in the pivotal cohort of its REMAIN-1 trial, a randomized, double-blind, sham-controlled study of Revita for weight maintenance after patients stop GLP-1 therapies such as tirzepatide. The study is designed to provide definitive evidence on Revita’s ability to limit weight regain and sustain prior weight loss, with topline six-month data expected in early Q4 2026, additional REVEAL-1 and REMAIN-1 cohort readouts scheduled throughout 2026, a potential FDA marketing application targeted for late Q4 2026, and a reaffirmed cash runway into early 2027 that positions the company to fund operations through these key clinical and regulatory milestones.

The REMAIN-1 pivotal cohort enrolls adults with obesity who achieved at least 15% total body weight loss on tirzepatide before discontinuation, then randomizes them 2:1 to Revita or a sham endoscopic procedure to compare weight regain at six months and maintenance of at least 5% weight loss at 12 months. Investigators report strong patient and physician interest driven by the clinical challenge of weight regain after GLP-1 cessation, underscoring a significant unmet need and highlighting Revita’s potential role in post-GLP-1 weight maintenance as Fractyl seeks U.S. regulatory clearance and strengthens its position in the emerging metabolic therapeutics landscape.

The most recent analyst rating on (GUTS) stock is a Hold with a $0.46 price target. To see the full list of analyst forecasts on Fractyl Health, Inc. stock, see the GUTS Stock Forecast page.

Spark’s Take on GUTS Stock

According to Spark, TipRanks’ AI Analyst, GUTS is a Neutral.

The score is held down primarily by very weak financial performance (minimal/declining revenue, large ongoing losses, heavy cash burn, and slightly negative equity). Technicals also lean bearish (below short-term moving averages with weak RSI/MACD). Offsetting these, earnings-call commentary was relatively positive due to encouraging clinical results, strong cash position/runway into early 2027, and clear 2026 milestones, but it is not enough to overcome current financial and momentum risks.

To see Spark’s full report on GUTS stock, click here.

More about Fractyl Health, Inc.

Fractyl Health, Inc. is a clinical-stage metabolic therapeutics company focused on novel treatments for obesity and type 2 diabetes, targeting organ-level dysfunction to achieve durable metabolic control without chronic therapy. Its lead product candidate, Revita, is a one-time, minimally invasive endoscopic procedure designed to remodel the duodenal lining, and has FDA Breakthrough Device designation for weight maintenance in people with obesity who discontinue GLP-1 therapies.

Average Trading Volume: 6,282,161

Technical Sentiment Signal: Sell

Current Market Cap: $66.33M

See more insights into GUTS stock on TipRanks’ Stock Analysis page.